skip to content
Dovepress - Open Access to Scientific and Medical Research
View our mobile site

8852

Pharmacotherapy in the management of early Parkinson’s disease: cost-effectiveness and patient acceptability

Review

(2038) Views  (626) Full article downloads

Authors: Esther Cubo

Published Date September 2010 Volume 2010:2 Pages 127 - 134
DOI: http://dx.doi.org/10.2147/CEOR.S11996

Esther Cubo

Neurology Department, Hospital General Yagüe, Burgos, Spain

Abstract: In the absence of a cure, the primary goals in managing Parkinson’s disease (PD) are to preserve functionality and health-related quality of life (HRQoL). Current therapeutic strategies for PD include symptomatic treatment and are primarily focused on replacing dopamine in the brain. Dopamine agonists can be used as an alternative initial levodopa therapy, to delay the onset of motor complications, but at the expense of more dopaminergic adverse effects; poorer control of motor symptoms; and increased cost. In PD, treatment effects and costs accumulate over time; hence the choice of time horizon in cost-effectiveness analysis can be particularly important. Pharmaceutical expenditures have grown rapidly in recent decades and now total nearly 10% of all health care costs. The main approach to treat PD at the present time is to advance knowledge of the efficacy, to reduce long-term complications associated with treatment, and to improve patient HRQoL and society burden. The implementation of cost-effectiveness studies, including the societal perspective, should be considered as an outcome of new therapy strategies, which would be helpful to health care decision makers.

Keywords: Parkinson’s disease, costs, health-related quality of life








Readers of this article also read:

Role of aliskiren in cardio-renal protection and use in hypertensives with multiple risk factors
Antihypertensive therapy among newly treated patients: An analysis of adherence and cost of treatment over years
On the decision rules of cost-effective treatment for patients with diabetic foot syndrome
Inpatient charges and mental illness: Findings from the Nationwide Inpatient Sample 1999–2007
Decline in hospitalization risk and health care cost after initiation of depot antipsychotics in the treatment of schizophrenia
Perception of risk and benefit in patient-centered communication and care
The relationship between deliberate self-harm behavior, body dissatisfaction, and suicide in adolescents: current concepts
Zinc oxide nanoparticles as selective killers of proliferating cells
Erratum
Cumulative clinical experience from over a decade of use of levofloxacin in community-acquired pneumonia: critical appraisal and role in therapy